SPARC and hyperparathyroidism: For illustration, diseases/drugs causing variations in calcium levels (hyperparathyroidism [27,28], vitamin D intake [29]) and collagen expression (collagenopathies [30]) could either limit/reduce the benefits of SPARC on bones or lead to side effects such as vascular calcification.